| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Maltooctaose serves as a substrate for enzymes such as amylases and maltases. It is used as a defined substrate for studying enzyme specificity and kinetics. It can be enzymatically synthesized using Pyrococcus furiosus thermostable amylase (PFTA). It is not a drug with a biological target but a research reagent.
|
|---|---|
| ln Vitro |
Pyrococcus furiosus, or PFTA, is a very unique enzyme that readily breaks apart certain cyclodextrin molecules to create maltooligosaccharides of particular lengths, most notably maltohexaose, maltoheptaose, and maltooctaose[1].
In vitro, Maltooctaose is used as a substrate in enzymatic assays to study amylase and maltase activity. It is hydrolyzed by amylases to release smaller maltooligosaccharides and glucose. It is used in glycobiology research and carbohydrate chemistry. |
| ln Vivo |
In vivo, Maltooctaose is not typically used as a therapeutic agent. It is a dietary carbohydrate that can be hydrolyzed by intestinal enzymes to release glucose. It may be used in studies of carbohydrate digestion and absorption. No specific pharmacological activities are reported.
|
| Enzyme Assay |
Cell-free enzyme assays for Maltooctaose: amylase or maltase activity is measured by incubating the enzyme with Maltooctaose in appropriate buffer at 37°C for 10-30 minutes. The release of glucose or smaller oligosaccharides is measured by reducing sugar assays (e.g., DNS method) or HPLC. Enzyme kinetics (Km, Vmax) are calculated.
|
| Cell Assay |
Cellular assays for Maltooctaose: intestinal epithelial cells (e.g., Caco-2 cells) are cultured and treated with Maltooctaose to study carbohydrate uptake and metabolism. Glucose transport and metabolism are measured. Cell viability is assessed by MTT assay. The compound is used to study intestinal carbohydrate digestion and absorption.
|
| Animal Protocol |
In vivo animal studies for Maltooctaose: animal models of carbohydrate metabolism are used. Animals are administered Maltooctaose orally. Blood glucose levels are monitored over time. Intestinal enzyme activity and glucose absorption are assessed. The compound is used to study the effects of oligosaccharides on glucose metabolism.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Maltooctaose: as a large oligosaccharide (molecular weight 1315.14), it is not absorbed intact. It is hydrolyzed by intestinal enzymes to release glucose, which is then absorbed. The compound is metabolized in the gastrointestinal tract. No systemic pharmacokinetics are applicable.
|
| Toxicity/Toxicokinetics |
Toxicity of Maltooctaose: as a dietary oligosaccharide, it is generally considered safe and non-toxic. High doses may cause gastrointestinal effects such as bloating and diarrhea due to osmotic effects. It is for research use only and not intended for human consumption.
|
| References | |
| Additional Infomation |
Maltooctaose is a research reagent used in carbohydrate chemistry and enzymology. It is available as a reference standard for enzymatic studies. Its primary application is as a defined substrate for amylases and maltases. No clinical applications or FDA approvals have been reported.
|
| Molecular Formula |
C48H82O41
|
|---|---|
| Molecular Weight |
1315.14010095596
|
| CAS # |
66567-45-1
|
| PubChem CID |
134830395
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
26
|
| Hydrogen Bond Acceptor Count |
41
|
| Rotatable Bond Count |
26
|
| Heavy Atom Count |
89
|
| Complexity |
2120
|
| Defined Atom Stereocenter Count |
38
|
| SMILES |
O([C@@H]1C([C@H]([C@@H]([C@H](CO)O1)O[C@@H]1C([C@H]([C@@H]([C@H](CO)O1)O[C@@H]1C([C@H]([C@@H]([C@H](CO)O1)O[C@@H]1C([C@H]([C@@H]([C@H](CO)O1)O)O)O)O)O)O)O)O)O)[C@@H]1[C@@H](CO)O[C@@H]([C@H]([C@@H]1O)O)O[C@@H]1[C@@H](CO)O[C@@H]([C@H]([C@@H]1O)O)O[C@@H]1[C@@H](CO)O[C@@H]([C@H]([C@@H]1O)O)O[C@@H]1[C@@H](CO)O[C@@H]([C@H]([C@@H]1O)O)O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7604 mL | 3.8019 mL | 7.6038 mL | |
| 5 mM | 0.1521 mL | 0.7604 mL | 1.5208 mL | |
| 10 mM | 0.0760 mL | 0.3802 mL | 0.7604 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
